EBIXA 5mg/pump actuation price in UAE

Overview

Welcome to Dwaey, specifically on EBIXA 5mg/pump actuation Solution (Oral) page.
This medicine contains an important and useful components, as it consists of Memantine HCl.
EBIXA 5mg/pump actuation is available in the market in concentration 10mg/ml 10mg/ml (equiv. to 8.32mg memantine) and in the form of Solution (Oral).

H. LUNDBECK A/S is the producer of EBIXA 5mg/pump actuation and it is imported from DENMARK, The most popular alternatives of EBIXA 5mg/pump actuation are listed downward .

Mode Of Action

Memantine, a derivative of amantadine, is a noncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist. It affects transmission of glutamate, the primary excitatory neurotransmitter in the CNS. Glutamate may contribute to the pathogenesis of Alzheimer's disease by overstimulating various glutamate receptors resulting in excitotoxicity and neuronal cell death.

Indication

Alzheimer's dementia.

Precaution

Renal impairment; epilepsy. Pregnancy and lactation. Closely monitor patients with recent MI, uncompensated CHF, uncontrolled hypertension. Predisposition to convulsions; conditions that increase urinary pH. Lactation: Unknown whether drug is excreted into breast milk; use with caution

Side Effects

1-10% Dizziness (7%)
Confusion (6%)
Headache (6%)
Constipation (5%)
Cough (4%)
Hypertension (4%)
Backache (3%)
Pain (3%)
Somnolence (3%)
Syncope (3%)
Vomiting (3%)
Dyspnea (2%)
Fatigue (2%) <1% Acute renal failure
Cerebral infarction
Cerebrovascular accident
Deep venous thrombosis
Hepatitis
liver failure
Intracranial hemorrhage
Neuroleptic malignant syndrome
Seizure (including grand mal)
Stevens-Johnson syndrome
Transient ischemic attack

Contra indication

Hypersensitivity to memantine or components of the formulation. Severe renal impairment.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Interaction

May increase effects of antimuscarinics and dopaminergics. May reduce effects of antipsychotics and barbiturates. May alter effects of dantrolene, baclofen. Reduced clearance with carbonic anhydrase inhibitors and sodium bicarbonate. Potentially Fatal: Increased risk of adverse effects with amantadine, dextromethorphan or ketamine.